Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships
As our understanding of genomics and genetic testing continues to advance, the personalization of medical decision making is progressing simultaneously. By carefully crafting medical care to fit the specific needs of the individual, patients can experience better long-term outcomes, reduced toxiciti...
Main Authors: | Austin A. Saugstad, Natasha Petry, Catherine Hajek |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Genetics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.857120/full |
Similar Items
-
Pharmacogenetics in Italy: current landscape and future prospects
by: Matteo Floris, et al.
Published: (2024-07-01) -
The concept of gene is in crisis. Does it affect pharmacogenetics and pharmacogenomics?
by: Miriam Falkenberg, et al.
Published: (2006-09-01) -
Pharmacogenetic Testing for the Pediatric Gastroenterologist: Actionable Drug–Gene Pairs to Know
by: Tracy Sandritter, et al.
Published: (2023-06-01) -
Application of pharmacogenetics in oncology
by: Nelly N. Miteva-Marcheva, et al.
Published: (2020-08-01) -
Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants
by: Julia Mestre, et al.
Published: (2024-10-01)